CClinicalTrials.gg
CompletedNCT01313156LUPSUpdated Aug 9, 2019

LUPS-Lipids and Glucose Under Prospective Surveillance

An observational study in Metabolic Syndrome and Type 2 Diabetes, sponsored by Asklepios proresearch. Completed at 2 sites in Germany. Open to participants aged 25 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-09.

Sponsored by Asklepios proresearch · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,962
Ages
25 Years to 60 Years
Sex
All
01

Study summary

Prospective, non-randomized cohort study to analyse genetic variations, dietary patterns, perceived stress and anxiety and early changes in lipid metabolism leading to the metabolic syndrome and type 2 diabetes

Read the detailed description

The LUPS-study is a collaboration between Asklepios Clinics Hamburg GmbH and University Clinic Hamburg Eppendorf, Germany. This study is assessing a multitude of serum biomarkers, anthropometrics, dietary habits, physical activity, perceived stress along with genetic information from "healthy workers" (25-60years) to better understand phenotype-genotype associations leading to MetS and type 2 diabetes.

02

Conditions studied

  • Metabolic Syndrome
  • Type 2 Diabetes

Keywords

  • Metabolic Syndrome, Syndrome X, MetS,
  • Type 2 Diabetes
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 1,962 is above the median of 300 across 1,588 observational studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Asklepios proresearch is the lead sponsor of 17 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

so-called "Healthy-Workers", aged 25-60years, of Lufthansa-Technik, Hamburg, Germany, who voluntarily aggreed to participate in the study.

Inclusion criteria

  • 25-60 years men and women willing to give consent

Exclusion criteria

Exclusion Criteria:

  • diabetes (type 1 or 2)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,962 participants (actual)
06

What researchers measure

Primary outcomes

  1. Metabolic Syndrome, Type 2 Diabetes

    assessing risk factors, e.g. HDL, BMI, Blood Pressure, FPG

    Time frame: 10 years

07

Study locations

2 sites
  • Asklepios Klinik St.Georg
    Hamburg, 20099, Germany
  • Universitätsklinikum Eppendorf
    Hamburg, 20246, Germany
08

References and documents

Publications

  • Muller-Wieland D, Altenburg C, Becher H, Burchard J, Frisch A, Gebhard J, Haas J, Harth V, Heeren J, Hengelbrock J, von Karais M, Knebel B, Kotzka J, Lowe B, Marx N, Pinnschmidt H, Preisser A, Rose M, Sawitzky-Rose B, Scheja L, Terschuren C, Toller M, Vettorazzi E, Wegscheider K. Development of the Metabolic Syndrome: Study Design and Baseline Data of the Lufthansa Prevention Study (LUPS), A Prospective Observational Cohort Survey. Exp Clin Endocrinol Diabetes. 2020 Dec;128(12):777-787. doi: 10.1055/a-0767-6361. Epub 2018 Nov 26. PubMed 30477037 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01313156
Lead sponsor
Asklepios proresearch
Collaborators
City of Hamburg, Universitätsklinikum Hamburg-Eppendorf
Responsible party
Sponsor
First posted
Mar 11, 2011
Start date
Nov 2008
Primary completion
Aug 2019
Completion
Aug 2019
Last update
Aug 9, 2019

Study contacts

Dirk Mueller-Wieland, Prof., MD
principal investigator · Asklepios Klinik St.Georg, Hamburg, Germany
Karl Wegscheider, Prof., PHD
principal investigator · Universitätsklinikum Hamburg-Eppendorf, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion